Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.

You may also be interested in...



In Brief: GSK, Bristol/Pfizer See Approvals, Baxter Holds Its Own in Hemophilia

Recent Phase III releases include data for Actavis’ ceftazidime/avibactam for gram-negative abdominal infections and Baxter’s long-acting Factor VIII hemophilia drug BAX 855. GSK’s fluticasone approved for asthma and Bristol/Pfizer’s Eliquis expands labeling.

With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory

FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.

GSK Completes Breo Ellipta Asthma Study For Potential NDA Filing

GSK reports positive results of a Phase III trial comparing the once-daily corticosteroid/long acting beta2-agonist combination Breo to the corticosteroid alone.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel